ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1814

Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients

Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus nephritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes
high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic
infections such as mycobacterium tuberculosis (Tbc). However, the efficacy of
isoniazid (INH) chemoprophylaxis has not been evaluated in lupus nephritis
patients.

The aim of this study was to investigate
the preventive effect of INH chemoprophylaxis on incidence of Tbc infection in
patients with lupus nephritis on immunosuppressive treatment.

Methods:
In this retrospective cohort study, 332 patients with lupus nephritis were
enrolled, who received glucocorticoids and immunosuppressive treatment at Seoul
National University Hospital between 2004 and 2015. Information on baseline
clinical characteristics and treatment were obtained from electronic medical
record review. Incidence rates of Tbc were compared
between patients who took INH prophylaxis (prophylaxis group) and those who did
not (non-prophylaxis group), using log-rank test. Then, incidence rates of Tbc
were investigated in subgroups of patients; those who received prednisolone >=
60 mg/day and high dose glucocorticoid pulse therapy.

Results:
A total of 332 patients with lupus nephritis were identified during the study
period. The mean age was 35.3 ±
14.8 years and 266 (80.1%) were female. Among 332 patients, sixty-nine (20.8%) patients
received INH prophylaxis and 263 (79.2%) patients did not. No case of Tbc
developed in 69 patients of INH prophylaxis group while 9 cases of Tbc developed
in 263 patients of non-prophylaxis group (0.0/100 person-years (PY) vs 0.53/100
PYs, p=0.236, by log-rank test). INH prophylaxis was effective neither in high
dose (>= 60 mg/day or its equivalents) prednisolone group (0.00/100 PYs vs 0.58/100
PYs, p=0.288, by log-rank test), nor in patients who received glucocorticoid
pulse therapy (0.00/100 PYs vs 0.69/100 PYs, p=0.161, by log-rank test). No
patient died of Tbc infection.

Conclusion:
In this retrospective review, INH chemoprophylaxis did not lead to
statistically significant prevention of Tbc in lupus nephritis patients.

Table 1. Isoniazid chemoprophylaxis in
patients with lupus nephritis

Prophylaxis

(n = 69)

Non-prophylaxis

(n = 263)

p-value

Age, mean ± SD years

37.78±13.47

34.60±15.07

0.092

Female sex (%)

55 (79.7)

211 (80.2)

0.924

Follow up duration,

mean ± SD years

3.74±2.59

6.48±3.65

<0.001

Prednisolone >= 60 mg/day (%)

45 (65.2)

74 (28.1)

<0.001

Steroid cumulative dose,

mean ± SD mg

27556.78±16875.22

21967.13±15196.75

0.014

Steroid pulse (%)

62 (89.9)

150 (57.0)

<0.001

Rituximab (%)

0 (0)

6 (2.3)

0.214

Mycophenolate mofetil (%)

16 (23.2)

144 (54.8)

<0.001

Tacrolimus (%)

23 (33.3)

57 (21.7)

0.057

Cyclophosphamide (%)

47 (68.1)

111 (42.2)

<0.001

Mycobacterium tuberculosis IR,

/100 person-years

0

0.53

0.496

Figure 1. Mycobacterium Tbc occurrence rate
in all lupus nephritis patients


Disclosure: J. Y. Moon, None; H. M. Kwon, None; E. Y. Ahn, None; J. K. Park, None; Y. W. Song, None; E. B. Lee, Pfizer Inc, 5.

To cite this abstract in AMA style:

Moon JY, Kwon HM, Ahn EY, Park JK, Song YW, Lee EB. Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-isoniazid-chemoprophylaxis-in-lupus-nephritis-patients/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-isoniazid-chemoprophylaxis-in-lupus-nephritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.